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Background: SNAT1 is a subtype of the amino acid transport system A that has been implicated to play a potential
role in cancer development and progression, yet its role in breast cancer remains unclear. In present study, we
detected SNAT1 expression in breast cancers and explored its underlying mechanism in promoting breast
carcinogenesis.
Methods: RT-PCR and Western blotting were performed to analyze the transcription and protein levels of SNAT1 in
breast cancer cell lines and fresh tissues. Tissue microarray blocks containing breast cancer specimens obtained
from 210 patients were constructed. Expression of SNAT1 in these specimens was analyzed using
immunohistochemical studies. SNAT1 was down-regulated by SNAT1-shRNA in breast cancer cells and the
functional significance was measured.
Results: SNAT1 was up-regulated in breast cancer cell lines and breast cancer tissues. Overexpression of SNAT1 was
observed in 127 cases (60.5%). Expression of SNAT1 was significantly associated with tumor size, nodal metastasis,
advanced disease stage, Ki-67, and ER status. Suppression of endogenous SNAT1 leads to cell growth inhibition,
cell cycle arrest, and apoptosis of 4T1 cells and lowered the phosphorylation level of Akt. SNAT1 expression
correlated significantly with p-Akt expression in human breast cancer samples.
Conclusions: The cross-talk between Akt signaling and SNAT1 might play a critical role in the development and
progression of breast cancer, providing an important molecular basis for novel diagnostic markers and new
attractive targets in the treatment of breast cancer patients.
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Breast cancer is the most frequently diagnosed cancer
and the leading cause of cancer-related death among fe-
males worldwide [1]. Due to early detection, progress in
treatment strategies and advances in our understanding
of the molecular mechanisms of breast cancer, thera-
peutic effect increases and patients have longer survival
duration. Unfortunately, global breast cancer incidence
is increasing and most of these patients inevitably die of
cancer recurrence and metastasis [2]. Therefore, it’s es-
sential to unveil the underlying mechanism of tumor
progression and develop effective therapeutic strategies.* Correspondence: dinghouzhong@hotmail.com; qiaoshanqian@gmail.com
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reproduction in any medium, provided the orSo far, several oncogenic kinase signaling pathways have
been considered as potential targets for cancer treat-
ment. Among these pathways, PI3K/Akt/mTOR signal-
ing has been shown to regulate cell proliferation,
growth, migration and energy metabolism [3-5]. Activa-
tion of Akt and its clinical value have been widely
reported in human breast cancer [4-7]. Recently, re-
searchers show that the amino acid carrier plays an im-
portant role in various cell life activities, including
energy metabolism, detoxication,neutrotransmission and
most importantly malignant transformation of mammal
cell. L-type amino acid transporter 1 (LAT1), for ex-
ample, was widely investigated in various human solid
tumors and increased expression of LAT1 was shown to
be associated with tumor size, advanced disease stages,
and Ki-67 labeling index and consequently with poor pa-
tient outcome [8-10]. Given the importance of Akttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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energy metabolism of tumor cells, we hypothesized that
Akt activation might be associated with up-regulation of
amino acid transporters [11].
Among these amino acid transporters, system A has
been found to be overexpressed in human solid cancers,
including glioma [12], hepatoceller carcinoma [13] and
hilar cholangiocarcinoma [14]. System A amino acid trans-
porter has three members: SNAT1, SNAT2, and SNAT4
(previously referred to as ATA1, ATA2, and ATA3, re-
spectively), encoded by the SLC38 gene family (Slc38a1,
Slc38a2, and Slc38a4) [15-17]. Among these three mem-
bers, SNAT1 was significantly elevated in hepatocellu-
lar carcinoma and cholangiocarcinoma [13,14]. Knocking
down endogenous SNAT1 inhibited cell proliferation of
HepG2 cells [13]. Moreover, SNAT1 expression signifi-
cantly correlated with tumor recurrence and poor out-
come of patients with changiocarcinoma [14]. However,
the expression pattern of SNAT1 and its role in breast
cancer development has not been fully demonstrated.
In the present study, we sought to determine the ex-
pression profiles of SNAT1 in breast cancers and cells
and to investigate its correlation with p-Akt. In vitro, we
further confirmed the association between SNAT1 ex-
pression and Akt activation, which controlled cell via-
bility and colony formation.
Methods
Materials
Recombinant murine EGF was purchased from Pepro-
Tech Inc. (Rocky Hill, NJ). phospho-Akt (Ser473) anti-
body was purchased from Cell Signaling Technology
(Beverly, MA). Anti-SLC38A1 antibody was from Abcam
Company (Cambridge, UK). ß-actin and Ki-67 antibodies
were from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell lines and culture conditions
The breast cancer cell lines MCF-7, MDA-MB-231 and
4T1 were purchased from the Cell Center of Chinese
Academy of Sciences, Shanghai, China. MCF-7, MDA-
MB-231 and 4T1 were maintained in DMEM with 10%
fetal bovine serum (FBS) (Invitrogen Corp., Grand Is-
land, NY). The cell lines were cultured in a 37°C hu-
midified atmosphere containing 95% air and 5% CO2.
Tissue samples and tissue microarray construction
Seventy patients with breast cancer from the Affiliated
Kunshan First People’s Hospital, Jiangsu Province, China
from 2007 to 2011 and 140 cases with breast cancer
from the Department of Oncology, Changzheng Hospital,
Shanghai, China from 2008–2011 were enrolled in this
study. Hematoxylin and eosin (HE) stained slides were
prepared and reviewed by two pathologists (Y.C. and G.Y.)
to ensure the quality of tissue blocks. The patients’ medicalrecords were reviewed to obtain data, including age at
diagnosis, tumor size, nodal metastases, and disease stage.
These patient characteristics are listed in Table 1. All of
these patients received no preoperative treatment, either
radiotherapy or chemotherapy.
Five paraffin-embedded tissue microarray blocks of
normal and tumor tissue specimens obtained from these
patients were created using a manual arrayer (Beecher In-
struments, Sun Prairie, WI, USA). Forty-five cases had
one 1.5-mm core of nonneoplastic tissue and two 1.5mm
cores of primary tumor tissues. The other cases only
had two 1.5mm cores of primary tumor tissue. Besides,
four fresh breast cancer tissues and matched fresh
nonneoplastic tissues were used to detect the expression
levels of SNAT1 mRNA and protein. Ethical review com-
mittees (Institutional Review Board of the Affiliated
Kunshan First People’s Hospital, Jiangsu University and
Institutional Review Board of Changzheng Hospital,
Shanghai) approved the use of all tissues and clinical infor-
mation (KS2008-01 and CZEC2001-01).RNA preparation and reverse transcription-polymerase
chain reaction
Total RNA was isolated from breast cancer cell lines and
homogenised breast cancer samples using the AB gene
Total RNA Isolation Reagent (Advanced Biotechnologies
Ltd., Epsom, Surrey, UK). RNA concentration and quality
were determined by spectrophotometric measurement
(WPA UV 1101, Biotech Photometer, Cambridge, UK).
cDNA was generated from 1 ug of each RNA sample and
a reverse transcribed using a transcription kit (Takara,
Kyoto, Japan). mRNA levels of SNAT1were assessed using
the specific oligonucleotide primer pairs SNAT1 (sense:
CCAGTGGCCTAGCTGGTACCAC and antisense: TCC
CCAGCGAAAGTTGACTCAGAC); As an internal con-
trol, we used the β-actin primers (sense: GCTGTCA
CCTTCACCGTTC and antisense: CCATCGTCCACC
GCAAAT).Immunohistochemical analysis and evaluation of
immunostaining
4 μm sections of paraffin-embedded tissue microarrays
blocks were prepared and processed for SNAT1 (dilution
1:50, ab59721; Abcam, Cambridge, UK) and p-Akt (dilu-
tion 1:50, 736E11; CST, Beverly, MA) proteins staining. A
S-p kit (KIT-9710; MAIXIN, Fuzhou, China) was used to
visualize antibody binding on the slides. Counterstaining
was performed with hematoxylin. All slices were evalu-
ated without knowledge of the expression of another
marker. SNAT1 and p-Akt protein expression in the 210
cases was evaluated by two individuals (C.Y. and G.Y.)
under an Olympus CX31 microscope (Olympus, Center
Valley, PA).
Table 1 Association between SNAT1 and p-Akt expression and clinicopathologic factors in breast cancer
Clinicopathological
variables
N (%) SNAT1 (%) P p-Akt (%) P
Positive Negative Positive Negative
Age(y)
<50 y 96(45.7) 58(60.4) 38(39.6) 0.987 64(66.7) 32(33.3) 0.509
≥50 y 114(54.3) 69(60.5) 45(39.5) 71(62.3) 43(37.7)
pT
pT1/2 174(82.9) 93(53.4) 81(46.6) <0.001 104(59.8) 70(40.2) 0.003
pT3/4 36(17.1) 34(94.4) 2(5.6) 31(86.1) 5(13.9)
pN
No 136(64.8) 58(42.6) 78(57.4) <0.001 64(47.1) 72(52.9) <0.001
Yes 74(35.2) 69(93.2) 5(6.8) 71(95.9) 3(4.1)
Disease stage
I/II 168(80.0) 85(50.6) 83(49.4) <0.001 96(57.1) 72(42.9) <0.001
III/IV 42(20.0) 42(97.6) 1(2.4) 39(92.9) 3(7.1)
Her2
+ 53(25.2) 32(60.4) 21(39.6) 0.986 37(69.8) 16(30.2) 0.332
- 157(74.8) 95(60.5) 62(39.5) 98(62.4) 59(37.6)
Ki67
+ 166(79.0) 109(65.7) 57(34.3) 0.003 112(67.5) 54(32.5) 0.061
- 44(21.0) 18(40.9) 26(59.1) 23(52.3) 21(47.7)
ER
+ 117(55.7) 60(47.2) 57(48.7) 0.002 67(57.3) 50(42.7) 0.017
- 93(44.3) 67(72.0) 26(28.0) 68(73.1) 25(26.9)
PR
+ 105(50.0) 60(57.1) 45(42.9) 0.323 70(66.7) 35(33.3) 0.471
- 105(50.0) 67(63.8) 38(36.2) 65(61.9) 40(38.1)
Total 210 127(60.5) 83(39.5) 135(64.3) 75(35.7)
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semiquantitative scoring system. Staining was graded on
a scale of 0–2 (0=negative staining [no staining of any
tumor cells], 1=weakly expression [staining of <25% of
tumor cells], and 2=high expression [staining of ≥25%
of tumor cells]). Only a score of 2 was regarded as
overexpression [18]. Staining was scored independently
by two individuals who were blinded to each other’s
findings.
Western blot analysis
Breast cancer cell lines, breast cancer specimens and
matched non-tumor tissues were prepared for Western
blot analyses. Standard Western blotting was performed
using a rabbit antibody against human SNAT1 (1:1000)
and p-Akt (1:1000) and an anti-rabbit IgG antibody,
which was a horseradish peroxidaselinked F(ab’)2 frag-
ments obtained from a donkey (Amersham). Equal pro-
tein sample loading was monitored by probing the same
membrane filter with an anti-β-actin antibody.Plasmids and transfections
The shRNA-SNAT1 and unspecific scrambled shRNA
plasmids were purchased from Genechem Company,
Shanghai, China. At 24 hours before transfection, 1×105
cells were seeded in six well plates. Transfection of shRNA
was carried out using Lipofectamine™ 2000 reagent
(Invitrogen, Karlsruhe, Germany) and 4 ng shRNA plas-
mid per well according to the manufacturer’s instructions.
Cell proliferation assay
At 12 hours after transfection, cells were digested and
5000 cells were seeded in 96-well plates and incubated
in medium with 10% FBS. At 24 h, 48 h, and 72 h, CCK8
assay (Dojindo Kumamoto, Japan) was performed to
measure the final results. The experiment was repeated
three times independently.
Colony formation assay
At 24 hours after transfection, cells were digested and
seeded in 6-well plates in triplicate at a density of 500
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with methanol/acetone (1:1) and stained with crystal vio-
let. Colonies with cell numbers of more than 50 cells per
colony were counted.
Flow cytometric analysis
Flow cytometric analysis was performed as described pre-
viously to determine the effects of SNAT1-shRNA on cell
cycle distribution and apoptosis [19,20]. Briefly, 4T1 cells,
grown in 6-well plates (2 × 105 cells/well), were synchro-
nized at the G1/S boundary after starvation with basal
medium for 24 hours, followed by transfection with
SNAT-shRNA or shRNA vector for 48 hours. At the indi-
cated time, cells were harvested by trypsinization and
fixed with 70% ethanol, and measured following the man-
ufacturer’s protocol (KEY GEN, Nanjing, China). Cell
cycle distribution and apoptosis was analyzed by flow cy-
tometry (FACSCalibur, BD Biosciences, Bedford, MA).
Statistical analysis
Statistical analysis was performed using the SPSS 16.0
statistical software program for Microsoft Windows.
Categorical data were analyzed using χ2 statistics tests.
Within-group correlations of continuous and ordinal
variables were assessed using Pearson’s R correlation
coefficient or Spearman correlation coefficient when ap-
propriate. The Kaplan-Meier method was used to esti-
mate survival rates, and the log-rank test was used to
assess survival differences between groups. The signifi-
cance of the in vitro results was determined by using the
Student t test (two tailed). Two-sided P value <0.05 was
considered statistically significant.SN    MCF-7   231     4T1 
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Figure 1 Expression patterns of SNAT1 in breast cancer cell lines and
overexpressed in MCF-7, MDA231, and 4T1 cells lines compared with norm
MDA231, and 4T1 cells lines compared with normal breast tissues (SN); (B1
cancer tissues (T) compared with that in matched noncancerous tissues (N
cancer tissues (T) compared with that in matched noncancerous tissues (NResults
SNAT1 expression in patients with breast cancer
To analyze the expression pattern of SNAT1 in breast
cancer, we firstly examined its mRNA and protein levels
in breast cancer cell lines and breast cancer specimens
and matched non-tumor tissues. As shown in Figure 1 A1
and B1, the level of SNAT1 mRNA was highly expressed
in cancer cell lines and cancers compared with non-
cancer tissues. Similarly, SNAT1 protein levels were eval-
uated in breast cancer cell lines and cancers compared
with non-cancer samples (Figure 1 A2 and B2). This re-
sult was further confirmed by immunohistochemistry.
Immunostaining showed that SNAT1 positive staining
was preferentially cytoplasm-localized. The epithelium in
normal breast samples showed negative or weakly SNAT1
expression (Figure 2A). However, drastically increased
SNAT1 expression was observed in the tumor cells
(Figure 2C). Interestingly, SNAT1 expression was up-
regulated in the tumor cells compared with the adjacent
non-cancerous breast epithelium from the same sample
(Figure 2D). Consistent with the mRNA data, this analysis
showed that SNAT1 protein level in breast cancer was re-
markably higher than that in normal adjacent epithelium.
Correlation between SNAT1 expression and
clinicopathologic characteristics of breast cancer
According to SNAT1 expression, the breast cancer pa-
tients were divided into two groups: SNAT1 negative ex-
pressers (n=83) and SNAT1 positive expressers (n=127).
Table 1 summarized the correlation between SNAT1 over-
expression and clinicopathological parameters in breast
cancer. No significant relationship was found betweenβ-actin
β-actin
N         T           N         T





human breast cancer specimens. (A1) SNAT1 mRNA was
al breast tissues (SN); (A2) SNAT1 protein was overexpressed in MCF-7,
) Overexpression of SNAT1 mRNA was observed in human breast











Figure 2 Analysis of SNAT1 expression in human breast
cancers and adjacent normal specimens. (A) Normal
(nonneoplastic) breast epithelium with negative expression of
SNAT1; (B) Negative SNAT1 expression in breast cancer specimens;
(C) Representative SNAT1 positive expression in breast cancer
specimens; (D) High level of SNAT1 expression in tumor cells (T) and
low SNAT1 expression in nonneoplastic breast epithelium (N); A1, B1,
C1, D1, D2: Enlargement of tissues in the frames from A, B, C, D,
respectively. Original magnification of A, B, C, D: 100×; Original
magnification of A1, B1, C1, D1-2: 400×.
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However, a statistically significant association was ob-
served between SNAT1 expression and tumor size, lymph
node metastasis, disease stage, Ki-67, and ER. Activation
of SNAT1 occurred more frequently in large breast tu-
mors (invasion to level T3-T4) (94.4%) than in small ones
(level T1-T2) (53.4%; P<0.001) and more frequently in
breast cancer with regional LN metastasis (93.2%) than in
N0-stage tumors (42.6%; P<0.001). In regard to TNM
stage, overexpression of SNAT1 was significantly asso-ciated with advanced disease stage: 97.6% at stage III /IV
and 50.6% at stage I/II (P<0.001). Moreover, SNAT1
upregulation correlated significantly with Ki-67 over-
expression (P=0.003) (Additional file 1: Figure S1) and
ER-negative expression (P=0.002).
Knockdown of SNAT1 by shRNA induces cell growth
inhibition and apoptosis of breast cancer cells by
blocking Akt phosphorylation
Given the fact that SNAT1 expression was prominently
activated in breast cancers, we further assessed the func-
tional significance and the underlying mechanism of
SNAT1 in breast cancer. As shown in Figure 3A, in 4T1
cells the transfection of SNAT1-shRNA results in a
sharply loss of SNAT1 protein expression at 48 hours after
the transfection. We also found that SNAT1 knockdown
reduced the level of phosphorylation of Akt in 4T1 cells
compared with the controls. When treated with 50 ng/ml
of EGF, both SNAT1 and p-Akt protein levels increased,
while the increase of p-Akt protein by EGF was partially
reversed by SNAT1-shRNA (Figure 3B). The knockdown
of SNAT1 significantly inhibited cell viability (Figure 3C)
as well as colony formation (Figure 3D) of 4T1 cells.
Meanwhile, SNAT1-downregulation leaded to cell cycle
arrested at G0/G1 and increased apoptosis of 4T1 cells
compared with shRNA empty vector transfected breast
cancer cells (Figure 3E, F). These results suggest that the
inhibitory effect of SNAT1-shRNA on 4T1 cells occurs
partially through blocking Akt phosphorylation.
p-Akt immunostaining was of cytoplasm- or nuclear-
localized. Negative or weakly expression of p-Akt was
found in normal breast samples (Figure 4A), while in-
creased expression of p-Akt was observed in 64.3%
(135/210) cases. As shown in Table 1, a significant asso-
ciation was observed between p-Akt expression and
tumor size, lymph node metastasis, advanced disease
stage, and ER negative expression. There was no signifi-
cant relationship between p-Akt expression and age,
HER, Ki67, and PR status.
Co-expression of p-Akt and SNAT1 in breast
cancer specimens
Table 2 presented that SNAT1 expression significantly
correlated with p-Akt expression (r=0.780, P<0.001). Co-
expression of p-Akt and SNAT1 were observed in 120
(57.1%) tumors, while 68 (32.4%) tumors showed no
expression of both. As shown in Figure 5, SNAT1 ex-
pression co-localized with p-Akt expression in the same
specimens.
Overexpression of SNAT1 and p-Akt on survival in
patients with breast cancer
The cohort consisted of 210 female patients with a


































Figure 3 Knockdown of SNAT1 induces cell growth inhibition, cell cycle arrested, and apoptosis of breast cancer cells by inhibiting
phosphorylation of Akt. (A) Western blot analysis of SNAT1 and p-Akt expression at 48 hours after the transfection of SNAT1-shRNA in 4T1 cells;
(B) SNAT1-shRNA inhibits EGF induces p-Akt phosphorylation. 4T1 cells were transfected with SNAT1-shRNA with or without the presence of
50 ng/ml EGF. (C) 4T1 cells were transfected with SNAT1-shRNA or scrambled shRNA-transfected cells (sc-shRNA) at indicated times (24, 48, and
72 hours) and cell proliferation assay was performed; (D) 4T1 cells transfected with SNAT1-shRNA and sc-shRNA were grown in 6-well plates were
incubated for 2 weeks. The numbers of the cell colonies were obtained and counted by 1-D gel quantity software QUANTITY ONE; (E) Cells were
transfected with SNAT1-shRNA and sc-shRNA for 48 h. Then the cells were collected and the apoptosis rates were detected by flow cytometry;
(F) After transfection for 48 h, 4T1 cells were harvested and cell cycle distributions were analyzed by flow cytometry. *P<0.05, ***P<0.001
considered statistically significant compared with sc-shRNA group.
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follow-up duration, 38 months; range, 19–51 months). To
the end of follow-up, only 12 of the 210 cases died of can-
cer. Of the 12 patients, 11 showed overexpression of
SNAT1 and 10 showed overexpression of p-Akt. Patients
with SNAT1 overexpression tumors had a significantlyshorter median survival duration (48.8 months) than
patients without SNAT1 overexpression tumors (50.8
months) (P = 0.025). Patients with p-Akt overexpression
tumors had shorter median survival duration (49.1
months) compared with those without p-Akt over-







Figure 4 Analysis of p-Akt expression in human breast cancers
and adjacent normal specimens. (A) Normal (nonneoplastic)
breast epithelium; (B) Negative p-Akt expression in breast cancer
specimens; (C, D) Representative p-Akt positive expression in breast
cancer specimens; A1, B1, C1, D1: Enlargement of tissues in the
frames from A, B, C, D, respectively. Original magnification of A, B, C,






Figure 5 Representative pictures showing co-expression of
SNAT1 and p-Akt in human breast cancers from the same
patients. Original magnification of the big pictures: 100×; Original
magnification of the small pictures: 400×.
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In this study, we found that up-regulation of SNAT1
was significantly associated with (1) tumor size, lymph
node metastasis and advanced disease stage, the most
important clinical determinants of treatment and prog-
nosis for breast cancer; (2) Ki-67 overexpression and
negative ER expression, the most important biomarker
guiding treatment and outcome for breast cancer; (3) el-




p-Akt - 68 7 <0.001 0.780
+ 15 120phosphorylated Akt (p-Akt). Moreover, knockdown of
SNAT1 blocked phosphorylation of Akt and hence at-
tenuated cell growth and induced apoptosis of human
breast cancer 4T1 cells. Therefore, we provided novel
molecular evidence that activation of SNAT1/Akt signal-
ing may play a critical role in breast cancer development
and progression.
Glutamine has various important functions in mamma-
lian cells and glutamine transport across cell membranes
has been extensively studied physiologically [21]. The
glutamine transporter (ATA1/SNAT1/SAT1/SLC38A1)
is a member of the system A transporter superfamily,
providing metabolic fuel or precursors for glutathione
synthesis [22]. Physiologically, this carrier is mainly dis-
tributed in placenta and brain tissues [21,23]. Recently,
researchers revealed overexpression of SNAT1 in human
solid malignant tumors, including hepatic carcinoma and
changiocarcinoma [13,14]. In the present study, SNAT1
expression was increased in breast cancer cells and tumor
specimens compared with normal tissues at both mRNA
and protein levels, suggesting oncogenetic role of SNAT1
in breast carcinogenesis. This result was further con-
firmed by immunostaining, which revealed a higher ex-









Figure 6 Prognostic value of SNAT1 and p-Akt expression in
patients with breast cancer. (A) Survival durations were
significantly worse in patients with positive expression of SNAT1
(median survival, 48.8 mo) than in those with negative expression
of SNAT1 (median survival, 50.8 mo; P= 0.025). (B) No significant
difference of survival durations were found between patients with
positive expression of p-Akt (median survival, 49.1 mo) and those
with negative expression of p-Akt (median survival, 50.3mo; P= 0.167).
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sues. Meanwhile, SNAT1 overexpression is closely cor-
related to tumor size, lymph node metastasis, disease
stage, Ki-67, and ER-negative expression, indicating
that SNAT1 is particularly important to breast cancer
progression. Interestingly, patients with SNAT1 over-
expression had a poor outcome than those without
SNAT1 overexpression, further supporting the potential
role of SNAT1 in cancer development and suggesting
SNAT1 as a good target for cancer therapy. However,
the relatively short follow-up duration limited the ex-
ploration of SNAT1 as an independent predictor of sur-
vival of breast cancer.
We then discovered that the knockdown of SNAT1
by specific shRNA reduced the viability of 4T1 cells.
This inhibition might due to cell cycle arrested and
apoptosis induced by downregulating SNAT1. Our dataare in line with a study showing that siRNA mediated
suppression of endogenous ATA1 lowered the viability
of HepG2 cells [13]. Take together, these siRNA or
shRNA experiments suggested the SNAT1 molecule is
essential in maintaining tumor survival. It has been
shown that maternal protein restriction in rat inhibits
Akt/mTOR signaling and down-regulates SNAT1 pro-
tein expression [24]. In this study, p-Akt level was
downregulated after transfection with SNAT1-shRNA
in 4T1 cells. In particular, this inhibition was also ob-
served for EGF-induced increase of p-Akt. These re-
sults provided a molecular basis for cross-talk between
Akt and SNAT1.
Activation of AKT in human cancers induces multiple
downstream cascades to promote cell survival, tumor
growth and progression. Deregulation of AKT signaling
was widely found in variety of human cancers including
breast cancer. Previous studies demonstrated that over-
expression of p-Akt was found in 30%~80% of cases
with breast cancers [4-7]. Similarly, our data showed
that p-Akt overexpression was observed in 64.3% cases
and correlated significantly with tumor size, lymph node
metastasis, disease stage, and ER-negative expression.
Interestingly, we found that p-Akt expression co-lo-
calized with SNAT1 expression in caner specimens from
the same patients. SNAT1(+)/p-Akt(+) was predomin-
antly found in 120 cases, while SNAT1(−)/p-Akt(−) was
in 68 cases, accounting 89.5% of all cases. This notion is
supported by a recent study showing that Akt/mTOR
signaling pathways and amino acid transporter activity
can be simultaneously down-regulated by chronic ma-
ternal infusion of full-length adiponectin in pregnant
mice [25]. Other studies also revealed an interaction be-
tween other amino acid transporters (SLC36A1 and
LAT1) and Akt signaling pathway [26,27]. Taken to-
gether, the cross-talk between Akt and SNAT1 might
play a critical role in cell growth and tumor metastasis.
However, whether decreased expression of p-Akt is a
feedback of cell growth inhibition by knocking down
SNAT1 or a direct downstream target of SNAT1 needs
further investigation.Conclusions
In summary, SNAT1 was frequently activated in human
breast cancer and its overactivation/overexpression was
associated with advanced tumor stage and nodal metas-
tasis. Additional in vitro study revealed that knockdown
of SNAT1 inhibited cell growth inhibition, cell cycle
arrested, and apoptosis of 4T1 cells by blocking the
phosphorylation of Akt. The cross-talk between Akt sig-
naling and SNAT1 provides an important molecular
basis for novel diagnostic markers and new attractive
targets in the treatment of breast cancer patients.
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Additional file 1: Figure S1. A significant association between SNAT1
and Ki-67 was observed in breast cancer specimens. (A) Representative
pictures showing co-expression of SNAT1 and Ki-67 in human breast cancers
from the same patient. Original magnification: 200× (B) Statistics showed a
significant correlation between SNAT1 and Ki-67 (r=0.206, P=0.003).
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